PL3220916T3 - Sposób leczenia raka n-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5-(etylo(tetrahydro-2h-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'-bifenylo]-3-karboksyamidem - Google Patents

Sposób leczenia raka n-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5-(etylo(tetrahydro-2h-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'-bifenylo]-3-karboksyamidem

Info

Publication number
PL3220916T3
PL3220916T3 PL15860676.4T PL15860676T PL3220916T3 PL 3220916 T3 PL3220916 T3 PL 3220916T3 PL 15860676 T PL15860676 T PL 15860676T PL 3220916 T3 PL3220916 T3 PL 3220916T3
Authority
PL
Poland
Prior art keywords
methyl
dihydropyridin
morpholinomethyl
pyran
carboxamide
Prior art date
Application number
PL15860676.4T
Other languages
English (en)
Polish (pl)
Inventor
Heike KEILHACK
Brett TRUITT
Yuta Suzuki
Tsukasa Murase
Futoshi SHIKATA
Original Assignee
Epizyme, Inc.
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme, Inc., Eisai R&D Management Co., Ltd. filed Critical Epizyme, Inc.
Publication of PL3220916T3 publication Critical patent/PL3220916T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
PL15860676.4T 2014-11-17 2015-11-17 Sposób leczenia raka n-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5-(etylo(tetrahydro-2h-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'-bifenylo]-3-karboksyamidem PL3220916T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US201562251903P 2015-11-06 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Publications (1)

Publication Number Publication Date
PL3220916T3 true PL3220916T3 (pl) 2023-08-14

Family

ID=56014476

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15860676.4T PL3220916T3 (pl) 2014-11-17 2015-11-17 Sposób leczenia raka n-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5-(etylo(tetrahydro-2h-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'-bifenylo]-3-karboksyamidem

Country Status (21)

Country Link
US (3) US10786511B2 (enExample)
EP (2) EP4272742A1 (enExample)
JP (3) JP6829684B2 (enExample)
KR (3) KR20240035908A (enExample)
CN (2) CN107249591B (enExample)
AU (3) AU2015350108B2 (enExample)
BR (1) BR112017010166A2 (enExample)
CA (1) CA2967664A1 (enExample)
DK (1) DK3220916T3 (enExample)
EA (1) EA201791095A1 (enExample)
ES (1) ES2947819T3 (enExample)
FI (1) FI3220916T3 (enExample)
HU (1) HUE062159T2 (enExample)
IL (4) IL296080B2 (enExample)
LT (1) LT3220916T (enExample)
MX (2) MX383484B (enExample)
PL (1) PL3220916T3 (enExample)
PT (1) PT3220916T (enExample)
SG (1) SG11201703806XA (enExample)
SI (1) SI3220916T1 (enExample)
WO (1) WO2016081523A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
BR112015008447A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc métodos para tratar câncer
WO2015085325A1 (en) 2013-12-06 2015-06-11 Epizyme, Inc. Combination therapy for treating cancer
KR20230031963A (ko) 2014-06-17 2023-03-07 에피자임, 인코포레이티드 림프종 치료를 위한 ｅｚｈ2 억제제
KR20240035908A (ko) 2014-11-17 2024-03-18 에피자임, 인코포레이티드 암을 치료하기 위한 방법
WO2016172199A1 (en) 2015-04-20 2016-10-27 Epizyme, Inc. Combination therapy for treating cancer
CA2988816A1 (en) 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
JP7121660B2 (ja) 2016-06-01 2022-08-18 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
CA3050221C (en) 2017-01-19 2021-09-28 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of htlv-1-associated myelopathy
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
BR112022012258A2 (pt) * 2019-12-20 2022-08-30 Epizyme Inc Sal cristalino de bromidreto de um inibidor de ezh2, sua preparação e composição farmacêutica útil para o tratamento de câncer
JP7628876B2 (ja) 2021-04-23 2025-02-12 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
US20250146080A1 (en) * 2022-02-17 2025-05-08 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
IL316421A (en) 2022-04-27 2024-12-01 Daiichi Sankyo Co Ltd Combination of an antibody-drug conjugate with an EZH1 and/or EZH2 inhibitor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119052D0 (en) 1991-09-06 1991-10-23 Boots Co Plc Pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
JP6389036B2 (ja) 2010-09-10 2018-09-12 エピザイム インコーポレイテッド ヒトｅｚｈ２の阻害剤、およびその使用方法
US20130296325A1 (en) * 2011-01-14 2013-11-07 Bristol-Myers Squibb Company HIGH DRUG LOAD TABLET FORMULATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
CA2867282C (en) * 2012-03-12 2024-04-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
RU2699546C2 (ru) 2012-04-13 2019-09-06 Эпизайм, Инк. Комбинированная терапия для лечения рака
PL3184523T3 (pl) * 2012-04-13 2019-12-31 Epizyme Inc Bromowodorek N-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5- (etylo(tetrahydro-2H-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'- bifenylo]-3-karboksyamidu do zastosowania w leczeniu zaburzenia proliferacji komórkowej układu hematologicznego
SG10201705989YA (en) 2012-10-15 2017-08-30 Epizyme Inc Substituted benzene compounds
BR112015008447A2 (pt) * 2012-10-15 2017-07-04 Epizyme Inc métodos para tratar câncer
US20150313906A1 (en) * 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
EP2935214B1 (en) 2012-12-21 2019-02-20 Epizyme, Inc. 1,4-pyridone compounds
WO2014100665A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
CA2903572A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
EP4324525A3 (en) 2013-10-16 2024-07-17 Epizyme, Inc. Hydrochloride salt form for ezh2 inhibition
US20160228447A1 (en) * 2013-10-18 2016-08-11 Epizyme, Inc. Method of treating cancer
WO2015085325A1 (en) 2013-12-06 2015-06-11 Epizyme, Inc. Combination therapy for treating cancer
KR20230031963A (ko) * 2014-06-17 2023-03-07 에피자임, 인코포레이티드 림프종 치료를 위한 ｅｚｈ2 억제제
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
CN106794177A (zh) 2014-10-16 2017-05-31 Epizyme股份有限公司 治疗癌症的方法
KR20240035908A (ko) 2014-11-17 2024-03-18 에피자임, 인코포레이티드 암을 치료하기 위한 방법
CA2988816A1 (en) * 2015-06-10 2016-12-15 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
MA45406A (fr) * 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer

Also Published As

Publication number Publication date
ES2947819T3 (es) 2023-08-21
MX2017006089A (es) 2017-12-11
IL252182B2 (en) 2023-02-01
JP2017537899A (ja) 2017-12-21
HUE062159T2 (hu) 2023-10-28
IL296080A (en) 2022-11-01
KR102338802B1 (ko) 2021-12-14
US20170360797A1 (en) 2017-12-21
US20210060030A1 (en) 2021-03-04
US12168014B2 (en) 2024-12-17
CN116650500A (zh) 2023-08-29
JP6829684B2 (ja) 2021-02-10
MX383484B (es) 2025-03-11
IL304252B1 (en) 2025-11-01
JP2021073241A (ja) 2021-05-13
EP3220916A1 (en) 2017-09-27
KR20240035908A (ko) 2024-03-18
LT3220916T (lt) 2023-07-25
BR112017010166A2 (en) 2018-02-14
JP2023062189A (ja) 2023-05-02
KR20170103768A (ko) 2017-09-13
NZ768247A (en) 2024-05-31
SG11201703806XA (en) 2017-06-29
IL304252A (en) 2023-09-01
CN107249591B (zh) 2024-01-30
EP3220916A4 (en) 2018-07-11
JP7485810B2 (ja) 2024-05-16
WO2016081523A1 (en) 2016-05-26
IL323396A (en) 2025-11-01
MX2021006734A (es) 2021-07-02
CN107249591A (zh) 2017-10-13
AU2015350108A1 (en) 2017-05-25
AU2021204706B2 (en) 2023-11-23
KR102644844B1 (ko) 2024-03-07
SI3220916T1 (sl) 2023-09-29
DK3220916T3 (da) 2023-06-26
EA201791095A1 (ru) 2017-10-31
US10786511B2 (en) 2020-09-29
AU2015350108B2 (en) 2021-04-08
FI3220916T3 (fi) 2023-06-19
IL252182B (en) 2022-10-01
CA2967664A1 (en) 2016-05-26
KR20210156840A (ko) 2021-12-27
AU2024201171A1 (en) 2024-03-14
IL252182A0 (en) 2017-07-31
EP4272742A1 (en) 2023-11-08
EP3220916B1 (en) 2023-04-19
PT3220916T (pt) 2023-06-26
IL296080B1 (en) 2023-08-01
IL296080B2 (en) 2023-12-01
AU2021204706A1 (en) 2021-07-29
NZ731696A (en) 2024-03-22
US20250064822A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
PL3220916T3 (pl) Sposób leczenia raka n-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5-(etylo(tetrahydro-2h-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'-bifenylo]-3-karboksyamidem
MX2016004703A (es) Forma salina de hidrocloruro para la inhibicion de ezh2.
IL256056A (en) ezh2 inhibitors for the treatment of lymphoma
DK3805233T3 (da) (r)- og (s)-enantiomerer af n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazol-carboxamid som irak4-hæmmere til cancerbehandling
DK2976360T3 (da) Terapi, hvori der er involveret antistoffer mod claudin 18.2, til behandling af cancer
LT3184523T (lt) N-((4,6-dimetil-2-okso-1,2-dihidropiridin-3-il)metil)-5-(etil (tetrahidro-2h-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-karboksamido hidrobromidas, skirtas naudoti hematologinės sistemos proliferacinio sutrikimo gydymui
DK3791896T3 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling
LT3468965T (lt) 1-tetrahidropiranilkarbonil-2,3-dihidro-1h-indolo junginiai vėžio gydymui
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
SI3097098T1 (sl) Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina
IL239981A0 (en) Combined therapy involving antibodies against claudin 18.2 for the treatment of cancer
HUE049413T2 (hu) Nazális porkészítmény hipoglikémia kezelésére
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
ZA201906047B (en) Compounds for treating tuberculosis
SMT202200458T1 (it) Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
BR112017009854A2 (pt) composto, uso de um composto, e, método para tratamento de leucemia.
PL2976360T3 (pl) Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego
LT3212644T (lt) 2-(1,2,4-triazol-3-ilsulfanil)-n-1,3,4-tiadiazol-2-ilacetamido dariniai, kurie yra naudotini diabeto gydymui
SG11201509680TA (en) Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.
GB201805557D0 (en) Therapy for ophthalmogical condtions
UA99119U (ru) N'-(2-(5-((теофиллин-7-ил)метил)-4-этил-4h-1,2,4-триазол-3-илтио)ацетил)изоникотиногидразид, который проявляет противотуберкулезную активность.
BR112017004947A2 (pt) composto ou sal farmaceuticamente aceitável, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento de mieloma múltiplo.
GB201400148D0 (en) Innovated method for treating tuberculosis through inhaling
SG10201403858RA (en) Compound, composition and method for treating and/or ameliorating kidney disease